antidepressants | CARLAT PUBLISHING

Psychopharm Commandment #6: MAOIs

March 20, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

CLINICAL UPDATE

Management of Depression and Neurocognitive Impairment in Patients With HIV

January 2, 2023

Garrett Rossi, MD.

Garrett Rossi, MD. Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center. Pomona, NJ.
Dr. Rossi has no financial relationships with companies related to this material.

Strategies for HIV-associated mood and cognitive changes

CLINICAL UPDATE

Viibryd Goes Generic, But Is It Worth Prescribing?

January 1, 2023

Chris Aiken, MD

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has no financial relationships with companies related to this material.

Goodbye Viibryd, hello vilazodone. This novel medication has missed the mark in a lot of trials, but it still has a narrow niche in the crowded field of antidepressants.

CARLAT WEBINAR

Black Box Warning in Children and Adolescents

December 19, 2022

Sandra Hyams, APRN, PMHNP

What's your role when prescribing antidepressants to your young patients?

How to Identify and Treat Apathy and Late-Life Depression

October 1, 2022

Rehan Aziz, MD and Julia Cromwell, MD

Rehan Aziz, MD. associate program director, geriatric psychiatry fellowship program, Jersey Shore University Medical Center; associate professor of psychiatry and neurology, Hackensack Meridian School of Medicine, Nutley, NJ. Julia Cromwell, MD. Inpatient geriatric psychiatrist, Mass General Brigham Salem Hospital, Salem, MA.

Dr. Aziz and Dr. Cromwell, authors of this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

We provide tips on distinguishing between apathy and depression, as well as recommendations on how to manage these disorders.

Research Update

Does Childhood Maltreatment Reduce Response to Antidepressant Treatment?

September 1, 2022

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH. Professor of Psychiatry at the Medical College of Georgia, Augusta, and President of the Georgia Psychiatric Physicians Association.

Dr. Miller, author of this educational activity, receives research support from Augusta University; the National Institute of Mental Health; the Brain and Behavior Research Foundation; and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

From response rates to adverse effects, this reanalysis of an older trial brings new answers on how a history of abuse and neglect affects antidepressant response.

Rethinking Topiramate

August 1, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Topiramate can cause psychosis, or treat psychosis; worsen cognition, or improve it; cause depression or… You get the point. A look at the paradoxical world of psychopharmacology.

What Gets in the Way of Antidepressants?

August 1, 2022

Chris Aiken, MD and Garrett Rossi, MD.

Garrett Rossi, MD.
Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Chris Aiken, MD.
Editor-in-Chief, The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC.

Dr. Rossi and Dr. Aiken, authors for this educational activity, have no relevant financial relationship(s) with ineligible companies to disclose.

Recent research has added to our understanding of factors that inhibit response to treatment, including major stress, nonadherence, and anxiety.

How Essential Is Antidepressant Continuation?

June 1, 2022

Michael Posternak, MD

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A landmark study puts a spotlight on whether patients can successfully taper off their antidepressant without relapsing.

Tricyclic Antidepressants: When and How to Use Them

May 1, 2022

Edmund S. Higgins, MD. Clinical associate professor, Psychiatry and Behavioral Sciences, Medical University of South Carolina. Dr. Higgins has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Tricyclics have been used in psychiatry since the 1950s, when imipramine was introduced as the first mass-marketed antidepressant. Fluoxetine and the other SSRIs largely supplanted the tricyclics in the 1990s, but these medications still have their uses.